<DOC>
	<DOC>NCT01378377</DOC>
	<brief_summary>The research trial is testing the experimental drug MSC1936369B (Pimasertib) and the drug TORISEL, given together, in the treatment of advanced solid tumors. The primary purpose of the study is to determine the maximum tolerated dose and the recommended Phase II dose (RP2D) of the drug combination.</brief_summary>
	<brief_title>Combination Trial MSC1936369B With Temsirolimus</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1. Subjects with histologically or cytologically confirmed solid tumors, either refractory to standard therapy or for which no effective standard therapy is available. 2. Measurable or evaluable disease at baseline by RECIST 1.0. 3. Age ≥ 18 years. 4. Subject has read and understands the informed consent form and is willing and able to give informed consent. 5. Performance Status score of ≤ 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. 6. Women of childbearing potential must have a negative blood pregnancy test at the screening visit. 7. Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for 2 weeks prior to screening, during the trial and for 3 months after the last dose of trial medication. Additional inclusion criteria also apply. 1. The subject has previously been treated with an mTOR inhibitor or a MEK inhibitor and taken off treatment due to drugrelated adverse events. 2. The subject has received any of the following: Chemotherapy, immunotherapy, hormonal therapy, biologic therapy, any investigational agent or any other anticancer therapy within 28 days (6 weeks for nitrosoureas or mitomycin C) of Day 1 of trial treatment; noncytotoxic chemotherapy or investigational agent with limited potential for delayed toxicity is permitted if terminated at least 5 halflives prior to Day 1 of trial treatment. Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation. 3. The subject has not recovered from toxicity due to prior therapy to baseline or Common Terminology Criteria for Adverse Events (CTCAE v4.0) of Grade 1 or less (except alopecia). 4. The subject has poor organ or marrow function 5. History of CNS metastases or primary CNS tumor, unless subject has been previously treated for these conditions, is asymptomatic and has had no requirement for anticonvulsants or high dose corticosteroids for a minimum of 2 weeks prior to entry into the trial. 6. History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months of Day 1 of trial drug treatment. 7. Recent major surgery or trauma (within the last 28 days), unhealing/open wounds, diabetic ulcers, recent drainage of significant volume of ascites or pleural effusion. 8. History of congestive heart failure, unstable angina, myocardial infarction, symptomatic cardiac conduction abnormality, pacemaker, or other clinically significant cardiac disease or history of a stroke within 3 months prior to entering the trial. 9. Baseline corrected QT interval on screening electrocardiogram (ECG) (QTc) ≥ 460 ms or left ventricular ejection fraction (LVEF) &lt; 40% on screening echocardiogram. 10. Other uncontrolled intercurrent diseases 11. Retinal degenerative disease (hereditary retinal degeneration or agerelated macular degeneration), history of uveitis or history of retinal vein occlusion, or medically relevant abnormal ophthalmology assessments at screening. 12. Known or suspected allergy to MSC1936369B, temsirolimus, other rapamycins (sirolimus, everolimus, etc.), their excipients, or any agent given in the course of this trial. 13. Immunization with attenuated live vaccines within one week of trial entry (examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, etc.). 14. Concomitant use of any medications or substances that are strong inhibitors or inducers of CYP3A enzyme, including, but not limited to, phenytoin, carbamazepine, barbiturates, azoles, rifampin, phenobarbital, or St. John's Wort. 15. Pregnant or lactating female. 16. Legal incapacity or limited legal capacity. Additional exclusion criteria also apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Phase I</keyword>
	<keyword>Pimasertib</keyword>
</DOC>